Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation

Reshef Tal, David Seifer, Aya Shohat-Tal, Richard V. Grazi, Henry E. Malter

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: To evaluate the relationship between transforming growth factor (TGF)-β1 and its receptor, soluble endoglin (sENG), in the serum and follicular fluid of women with polycystic ovarian syndrome (PCOS) compared with that of non-PCOS normal ovulating women during controlled ovarian stimulation (COS). Design: Prospective case-control study. Setting: Academic-affiliated assisted reproductive technology unit. Patient(s): Fourteen PCOS and 14 matched non-PCOS control women undergoing COS. Intervention(s): Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-β1 and sENG protein levels. Main Outcome Measure(s): Serum and FF levels of TGF-β1 and sENG. Result(s): Serum TGF-β1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-β1 (TGF-β1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups. Conclusion(s): The increased TGF-β1 bioavailability in PCOS is not only due to increased TGF-β1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-β1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.

Original languageEnglish (US)
Pages (from-to)538-543
Number of pages6
JournalFertility and Sterility
Volume100
Issue number2
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Ovulation Induction
Polycystic Ovary Syndrome
Transforming Growth Factors
Follicular Fluid
Serum
Biological Availability
Oocyte Retrieval
Endoglin
Assisted Reproductive Techniques
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)
Control Groups

Keywords

  • angiogenesis
  • controlled ovarian stimulation (COS)
  • Polycystic ovarian syndrome (PCOS)
  • soluble endoglin (sENG)
  • transforming growth factor-β1 (TGF-β1)

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. / Tal, Reshef; Seifer, David; Shohat-Tal, Aya; Grazi, Richard V.; Malter, Henry E.

In: Fertility and Sterility, Vol. 100, No. 2, 08.2013, p. 538-543.

Research output: Contribution to journalArticle

Tal, Reshef ; Seifer, David ; Shohat-Tal, Aya ; Grazi, Richard V. ; Malter, Henry E. / Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. In: Fertility and Sterility. 2013 ; Vol. 100, No. 2. pp. 538-543.
@article{0770a070c7e448a1b642d8e48ee833b6,
title = "Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation",
abstract = "Objective: To evaluate the relationship between transforming growth factor (TGF)-β1 and its receptor, soluble endoglin (sENG), in the serum and follicular fluid of women with polycystic ovarian syndrome (PCOS) compared with that of non-PCOS normal ovulating women during controlled ovarian stimulation (COS). Design: Prospective case-control study. Setting: Academic-affiliated assisted reproductive technology unit. Patient(s): Fourteen PCOS and 14 matched non-PCOS control women undergoing COS. Intervention(s): Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-β1 and sENG protein levels. Main Outcome Measure(s): Serum and FF levels of TGF-β1 and sENG. Result(s): Serum TGF-β1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-β1 (TGF-β1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups. Conclusion(s): The increased TGF-β1 bioavailability in PCOS is not only due to increased TGF-β1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-β1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.",
keywords = "angiogenesis, controlled ovarian stimulation (COS), Polycystic ovarian syndrome (PCOS), soluble endoglin (sENG), transforming growth factor-β1 (TGF-β1)",
author = "Reshef Tal and David Seifer and Aya Shohat-Tal and Grazi, {Richard V.} and Malter, {Henry E.}",
year = "2013",
month = "8",
doi = "10.1016/j.fertnstert.2013.04.022",
language = "English (US)",
volume = "100",
pages = "538--543",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation

AU - Tal, Reshef

AU - Seifer, David

AU - Shohat-Tal, Aya

AU - Grazi, Richard V.

AU - Malter, Henry E.

PY - 2013/8

Y1 - 2013/8

N2 - Objective: To evaluate the relationship between transforming growth factor (TGF)-β1 and its receptor, soluble endoglin (sENG), in the serum and follicular fluid of women with polycystic ovarian syndrome (PCOS) compared with that of non-PCOS normal ovulating women during controlled ovarian stimulation (COS). Design: Prospective case-control study. Setting: Academic-affiliated assisted reproductive technology unit. Patient(s): Fourteen PCOS and 14 matched non-PCOS control women undergoing COS. Intervention(s): Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-β1 and sENG protein levels. Main Outcome Measure(s): Serum and FF levels of TGF-β1 and sENG. Result(s): Serum TGF-β1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-β1 (TGF-β1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups. Conclusion(s): The increased TGF-β1 bioavailability in PCOS is not only due to increased TGF-β1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-β1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.

AB - Objective: To evaluate the relationship between transforming growth factor (TGF)-β1 and its receptor, soluble endoglin (sENG), in the serum and follicular fluid of women with polycystic ovarian syndrome (PCOS) compared with that of non-PCOS normal ovulating women during controlled ovarian stimulation (COS). Design: Prospective case-control study. Setting: Academic-affiliated assisted reproductive technology unit. Patient(s): Fourteen PCOS and 14 matched non-PCOS control women undergoing COS. Intervention(s): Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-β1 and sENG protein levels. Main Outcome Measure(s): Serum and FF levels of TGF-β1 and sENG. Result(s): Serum TGF-β1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-β1 (TGF-β1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups. Conclusion(s): The increased TGF-β1 bioavailability in PCOS is not only due to increased TGF-β1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-β1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.

KW - angiogenesis

KW - controlled ovarian stimulation (COS)

KW - Polycystic ovarian syndrome (PCOS)

KW - soluble endoglin (sENG)

KW - transforming growth factor-β1 (TGF-β1)

UR - http://www.scopus.com/inward/record.url?scp=84881191708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881191708&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2013.04.022

DO - 10.1016/j.fertnstert.2013.04.022

M3 - Article

C2 - 23684116

AN - SCOPUS:84881191708

VL - 100

SP - 538

EP - 543

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -